Loading…
← CockpitCompetitor Analysis › SLN Silence Therapeutics PLC Sponsored ADROpen in the cockpit ↗

Silence Therapeutics PLC Sponsored ADRSLNCompetitor analysis, valuation and peers

United States · USD·Health Care›Miscellaneous Commercial Services
Momentum leader 99
Mkt cap
$1.23B
US dollars, full cap
Free float
84%
of shares outstanding
$/day
$28.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 11.7%
Hurdle
n/a
no reverse DCF
Next earnings
119 days
17 Mar 2027
Close · USD$19.82
1D+0.1%
1W+0.2%
1M+1.1%
3M+50.5%
6M+243.5%
YTD+226.0%
1Y+190.2%
ATR %1.6%
Beta1.39
52w lowhigh0.2% off high

What Silence Therapeutics PLC Sponsored ADR does

Employees: 88

Silence Therapeutics PLC Sponsored ADR at a glance

Size Silence Therapeutics PLC Sponsored ADR (SLN) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $1.23B, the 2100th largest of 3,085 United States companies the cockpit tracks. Shares closed at $19.82 on 18 Nov 2026.

Performance Over six months the shares gained 243.5%, against +1.8% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 10 in its peer set.

Growth Revenue fell 97.8% over the last twelve months (peer median +6.1%); the operating margin is -11,919.9% (peer median -1.3%).

Valuation It trades at 2,161.6× enterprise value to sales against a peer median of 1.9× (most expensive of 8).

Short interest Short interest is 3.9% of the free float (30 Oct 2026).

Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026SLN 318Peer median 102
Six months, rebased to 100: Silence Therapeutics PLC Sponsored ADR against the median of its 9 peers (local-currency closes).

Silence Therapeutics PLC Sponsored ADR financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$455,244$560,306$43.3M$31.8M$21.6M
Revenue growth—-99%+36%+47%—
Gross profit$11,460-$55,129$31.2M$18.6M$7.56M
EBITDA-$53.8M-$81.9M-$49.0M-$52.0M-$59.3M
Net income-$51.4M-$88.8M-$45.3M-$54.4M-$49.9M
Free cash flow-$44.1M-$62.5M-$67.9M-$49.7M-$56.1M
Capital expenditure-$70$55,129$211,089$56,217$541,983
Total debt$87,000$160,000$117,000$346,000$536,493

Quarterly statements and history in the cockpit →

Silence Therapeutics PLC Sponsored ADR competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%FTREOABISBCANLPGNYEVTOCSEVHTECXSLN6-month return →1-month return →
Up and to the right = strong over both horizons. Silence Therapeutics PLC Sponsored ADR is the large dot.

Fundamentals: revenue growth against valuation

-100%-50%0%+50%+100%0×1,000×2,000×FTREOABISBCSLNRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Silence Therapeutics PLC Sponsored ADR is the large dot.

Silence Therapeutics PLC Sponsored ADR competitors and peer comparison

How Silence Therapeutics PLC Sponsored ADR compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Silence Therapeutics PLC Sponsored ADR against its 9 peers (data as of 18 Nov 2026)
MeasureSLNPeer medianRank in peer set
1-month return+1.1%-1.3%4th highest of 10
6-month return+243.5%+1.8%highest of 10
Distance from 52-week high-0.2%-37.2%highest of 10
Revenue growth (TTM)-97.8%+6.1%lowest of 7
Operating margin-11,919.9%-1.3%lowest of 8
EV / Sales2,161.6×1.9×most expensive of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Silence Therapeutics PLC Sponsored ADR SLNUnited States$1.23B+244%-98%-11,920%2,161.6×n/an/a
Fortrea FTREUnited States$1.98B+50%-3%2%1.1×31.9%+1.1%
OmniAb OABIUnited States$741M+97%+91%-116%17.3×60.6%-31.9%
SBC Medical SBCUnited States$645M+94%+7%40%2.6×-15.7%+6.7%
Adlai Nortye Ltd. Sponsored ADR ANLUnited States$610M-23%n/a-134%22.3×n/an/a
Progyny PGNYUnited States$2.66B+41%+6%9%1.9×8.6%+30.2%
Evotec EVT.DEGermany$532M-46%-5%-15%0.8×n/an/a
Oculis OCSUnited States$456M-74%n/an/an/an/an/a
Evolent Health EVHUnited States$445M+2%+14%-1%0.5×14.0%+15.2%
Tectonic Therapeutic TECXUnited States$420M-27%n/an/an/an/an/a

Questions

Which companies are Silence Therapeutics PLC Sponsored ADR's closest peers?
The cockpit's peer set: Fortrea (FTRE), OmniAb (OABI), SBC Medical (SBC), Adlai Nortye Ltd. Sponsored ADR (ANL), Progyny (PGNY), Evotec (EVT.DE), Oculis (OCS), Evolent Health (EVH).
Is Silence Therapeutics PLC Sponsored ADR expensive compared with its peers?
On ev / sales it trades at 2,161.6× against a peer median of 1.9×, most expensive of 8 in its peer set.
How has Silence Therapeutics PLC Sponsored ADR stock performed?
Over six months to 18 Nov 2026 the shares returned +243.5% against +1.8% for the median peer; over one year +190.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.